FAT EMBOLISM SYNDROME AFTER FEMORAL FRACTURE: EARLY RECOGNITION, DIAGNOSTIC CONFIRMATION, AND THERAPEUTIC STRATEGY

Abstract

DOI: https://doi.org/10.46296/yc.v10i19.0965

Abstract

Background: Fat embolism syndrome (FES) is an uncommon but potentially life-threatening complication of femoral and other long-bone fractures. Its diagnosis remains difficult because no validated gold-standard test exists, and the classic triad of hypoxemia, neurologic dysfunction, and petechiae is often incomplete. This updated systematic review summarizes evidence relevant to early recognition, diagnostic confirmation, prevention, and treatment. Methods: A multidomain evidence update was performed through 30 August 2026. The historical epidemiologic evidence base was anchored to a prior systematic review of femoral fractures (1960–2019), and PubMed/MEDLINE, PubMed Central, and backward citation searches were used to identify contemporary cohort, diagnostic, randomized, and high-value synthesis studies. Evidence was synthesized qualitatively because diagnostic definitions, populations, and interventions were heterogeneous. Results: The historical review included 15 studies (n=3,095) and documented a fall in clinically diagnosed FES from 7.9% in 1960–1979 to 1.7% in 2000–2019. Contemporary administrative cohorts report much lower coded incidence (approximately 0.03–0.04%), whereas a 2026 trauma-center cohort reported 4.3%, highlighting persistent case-definition effects. Femoral fracture, multiple long-bone fractures, younger age, and high-energy trauma consistently increase risk. New hypoxemia and neurologic deterioration within 12–72 h are the most useful early signals; petechiae are specific when present but insensitive. Gurd–Wilson and Schonfeld criteria remain supportive rather than confirmatory. Chest CT can demonstrate bilateral ground-glass or centrilobular opacities but is nonspecific; brain MRI with diffusion-weighted imaging and susceptibility-weighted imaging provides the strongest imaging support for cerebral FES. Bronchoalveolar lavage fat-laden macrophages lack adequate specificity. The therapeutic cornerstone is organ support and timely fracture stabilization when physiologically appropriate. Older randomized trials suggest that prophylactic corticosteroids reduce FES and hypoxemia, but the evidence is small, dated, and methodologically limited, with no proven mortality benefit. Conclusions: FES should be treated as a time-sensitive clinicoradiologic diagnosis of exclusion. A structured first-72-hour surveillance strategy, early investigation of unexplained hypoxemia or neurologic change, selective MRI confirmation, and modern supportive critical care offer the most defensible approach. Routine disease-specific anticoagulation or corticosteroid therapy for established FES cannot be recommended from current evidence.

Keywords: fat embolism syndrome; femoral fracture; long-bone fracture; hypoxemia; cerebral fat embolism; magnetic resonance imaging; fracture fixation; trauma.